Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IBC 2025 | Findings from a sequencing study evaluating tumor & immune cells in pts with MGUS, SMM & myeloma

Romanos Sklavenitis-Pistofidis • 13 Mar 2025
IBC 2025
Multiple Myeloma Smoldering Myeloma

In this video, Romanos Sklavenitis-Pistofidis, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares findings from a large single-cell sequencing study evaluating tumor and immune cells in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and overt multiple myeloma, sharing insights into the impact of cytotoxic T-cells. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Romanos Sklavenitis-Pistofidis

Single-cell RNA-sequencing of 6 million tumor and immune cells from patients with MGUS and SMM 4:18
Single-cell RNA-sequencing of 6 million tumor and immune cells from patients with MGUS and SMM
Romanos Sklavenitis-Pistofidis • 7 Dec 2024
A single-cell RNA analysis of tumor and immune cells in asymptomatic and overt WM 4:19
A single-cell RNA analysis of tumor and immune cells in asymptomatic and overt WM
Romanos Sklavenitis-Pistofidis • 18 Oct 2024
Sub-typing Waldenström’s macroglobulinemia: memory B-cell subtype and plasma cell-like subtype 1:51
Sub-typing Waldenström’s macroglobulinemia: memory B-cell subtype and plasma cell-like subtype
Romanos Sklavenitis-Pistofidis • 18 Oct 2024
Improving the risk stratification of patients with smoldering myeloma 1:53
Improving the risk stratification of patients with smoldering myeloma
Romanos Sklavenitis-Pistofidis • 26 Sep 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals